---
title: "LifeMD | 8-K: FY2026 Q1 Revenue: USD 50.16 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285440645.md"
datetime: "2026-05-06T21:07:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285440645.md)
  - [en](https://longbridge.com/en/news/285440645.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285440645.md)
---

# LifeMD | 8-K: FY2026 Q1 Revenue: USD 50.16 M

Revenue: As of FY2026 Q1, the actual value is USD 50.16 M.

EPS: As of FY2026 Q1, the actual value is USD -0.2.

EBIT: As of FY2026 Q1, the actual value is USD -8.986 M.

#### Total Revenue

LifeMD, Inc. reported total revenue of $50.2 million for the first quarter of 2026, a -1% year-over-year change compared to $50.9 million in the prior-year period. The majority of this revenue was derived from recurring subscriptions, and the Q1 2026 revenue exceeded the company’s guidance range of $48 million to $49 million.

#### Gross Profit and Margin

Gross profit increased 3% to $44.2 million in Q1 2026. Gross margin expanded to 88% in Q1 2026, up approximately 420 basis points from 84% in the prior-year period, primarily due to product mix.

#### Net Loss

The GAAP net loss from continuing operations attributable to common stockholders was - $9.6 million, or - $0.20 per share, for Q1 2026, compared with a GAAP net loss from continuing operations of - $2.4 million, or - $0.06 per share, in the prior-year period. The net loss attributable to LifeMD, Inc. common stockholders was - $9,649,159 for Q1 2026, compared to - $960,341 for Q1 2025.

#### Adjusted EBITDA

Adjusted EBITDA loss was - $4.5 million for Q1 2026, compared with adjusted EBITDA of $3.7 million in the prior-year period, reflecting a -219% year-over-year change, primarily due to a planned opportunistic increase in patient acquisition spend.

#### Operating Expenses

Selling and marketing expenses increased 34% to $29.9 million, reflecting strategic, front-loaded patient acquisition investments. General and administrative expenses were $15,176,355 in Q1 2026 compared to $14,340,151 in Q1 2025. Total expenses amounted to $53,166,529 for Q1 2026, up from $43,933,154 in Q1 2025.

#### Cash and Debt

LifeMD, Inc. exited the quarter with $34.5 million in cash and no debt as of March 31, 2026. The company also had a $30 million undrawn revolving credit facility.

#### Operating Cash Flow

Net cash provided by operating activities of continuing operations was $444,624 for Q1 2026, compared to $258,826 for Q1 2025.

#### Subscriber Growth

LifeMD, Inc. added more than 42,000 net telehealth subscribers in Q1 2026, marking the largest quarterly net addition in its history. The company ended the quarter with over 365,000 subscribers, an increase of approximately 26% year-over-year.

#### Weight Management

Weight management new-patient revenues grew approximately 120% versus the fourth quarter of 2025. The number of Weight Management program subscribers was just under 100,000 at quarter-end.

#### Women’s Health

Women’s Health patient signups experienced 657% quarter-over-quarter growth, with approximately 70% reduction in customer acquisition costs.

#### Outlook / Guidance

For the second quarter of 2026, LifeMD, Inc. expects revenue in the range of $47 million to $50 million and adjusted EBITDA of - $2 million to $1 million. For the full year 2026, the company affirmed its guidance of revenue between $220 million and $230 million, representing 13% to 19% year-over-year growth, and adjusted EBITDA in the range of $12 million to $17 million. Annualized run-rate revenue is expected to exceed $250 million and annualized run-rate adjusted EBITDA is expected to exceed $25 million by Q4 2026.

### Related Stocks

- [LFMD.US](https://longbridge.com/en/quote/LFMD.US.md)

## Related News & Research

- [LifeMD to Participate in Upcoming Investor Conferences | LFMD Stock News](https://longbridge.com/en/news/286561977.md)
- [LifeMD Q1 revenue beats estimates on record telehealth subscriber additons](https://longbridge.com/en/news/285436217.md)
- [Lake Street Keeps Their Buy Rating on LifeMD (LFMD)](https://longbridge.com/en/news/270855288.md)
- [BUZZ-LifeMD rises after adding new daily obesity pill to weight management program](https://longbridge.com/en/news/282347000.md)
- [LifeMD Q4 revenue rises but misses estimates](https://longbridge.com/en/news/278442977.md)